Loading…
← CockpitCompetitor Analysis › PACB Pacific Biosciences of California, Inc.Open in the cockpit ↗

Pacific Biosciences of California, Inc.PACBCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 96
Mkt cap
$573M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$30.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-38.4 pp
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
92 days
18 Feb 2027
Close · USD$1.83
1D+0.6%
1W-12.4%
1M-6.6%
3M+48.8%
6M+53.8%
YTD-2.1%
1Y+16.6%
ATR %13.9%
Beta2.04
52w lowhigh46.7% off high

What Pacific Biosciences of California does

Employees: 485

Pacific Biosciences of California at a glance

Size Pacific Biosciences of California (PACB) is a United States Health Care company (Medical Specialties) with a market value of $573M, the 2575th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.83 on 18 Nov 2026.

Performance Over six months the shares gained 53.8%, against -2.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 4.4% over the last twelve months (peer median +14.4%); the operating margin is -98.1% (peer median 7.4%).

Valuation It trades at 6.7× enterprise value to sales against a peer median of 5.5× (7th most expensive of 20).

Capital Return on invested capital runs 38.4 points below its cost of capital (10.3% WACC).

Backlog Backlog (remaining performance obligations) was $43.8M at 30 Sep 2026, down 10% on a year earlier — 0.3 years of trailing revenue. Backlog detail →

Short interest Short interest is 17.1% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026PACB 146Peer median 98
Six months, rebased to 100: Pacific Biosciences of California against the median of its 20 peers (local-currency closes).

Pacific Biosciences of California financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$161M$160M$154M$201M$128M
Revenue growth—+4%-23%+56%—
Gross profit$52.5M-$319M$23.7M$40.3M$48.9M
EBITDA-$141M-$165M-$212M-$278M-$288M
Net income-$131M-$546M-$310M-$307M-$314M
Free cash flow-$143M-$114M-$212M-$275M-$280M
Capital expenditure$13.5M$7.71M$6.19M$8.84M$16.9M
Total debt$705M$702M$675M$934M$949M

Quarterly statements and history in the cockpit →

Pacific Biosciences of California competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%300952301235603122OBIO300314688581TCMDSGHT300869ZJYL688236MYGNRCELPACB6-month return →1-month return →
Up and to the right = strong over both horizons. Pacific Biosciences of California is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×10×20×300952301235603122OBIOTCMDVVVVMEDI605369ZJYLRCEL4728PACBRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pacific Biosciences of California is the large dot.

Pacific Biosciences of California competitors and peer comparison

How Pacific Biosciences of California compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pacific Biosciences of California against its 20 peers (data as of 18 Nov 2026)
MeasurePACBPeer medianRank in peer set
1-month return-6.6%-0.8%7th lowest of 19
6-month return+53.8%-2.1%4th highest of 19
Distance from 52-week high-46.7%-31.6%6th lowest of 20
Revenue growth (TTM)+4.4%+14.4%8th lowest of 20
Operating margin-98.1%7.4%2nd lowest of 20
EV / Sales6.7×5.5×7th most expensive of 20
ROIC minus cost of capital-38.4 pp-1.3 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%18.3×n/an/a
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%5.4×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%3.7×0.4%+27.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%1.5×8.4%+12.0%
vVARDIS VVVVUnited States$594Mn/a+148%-72%14.3×n/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%6.4×n/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%7.1×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%3.8×35.3%+6.7%
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%6.3×35.9%+35.2%
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Beijing Chunlizhengda Medical Instruments 688236.SSChina$618M-27%-13%31%2.1×-8.5%+2.2%
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%8.3×-2.6%+18.8%

Pacific Biosciences of California backlog

Pacific Biosciences of California reported $43.8M of remaining performance obligations at 30 Sep 2026, down 10% from a year earlier and down 9% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 0.90.

Questions

Which companies are Pacific Biosciences of California's closest peers?
The cockpit's peer set: Jiangsu Hanvo Safety Product (300952.SZ), Wuhan Huakang Century Clean Technology (301235.SZ), Cowealth Medical China (603122.SS), Orchestra BioMed (OBIO), Ningbo David Medical Device (300314.SZ), Hangzhou AGS MedTech (688581.SS), Tactile Systems Technology (TCMD), vVARDIS (VVVV).
Is Pacific Biosciences of California expensive compared with its peers?
On ev / sales it trades at 6.7× against a peer median of 5.5×, 7th most expensive of 20 in its peer set.
How has Pacific Biosciences of California stock performed?
Over six months to 18 Nov 2026 the shares returned +53.8% against -2.1% for the median peer; over one year +16.6%.
What is Pacific Biosciences of California's backlog?
Pacific Biosciences of California's remaining performance obligations (contracted revenue not yet recognised) were $43.8M at 30 Sep 2026, -10% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.